Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer

Author's Avatar
Mar 01, 2022

Janux+Therapeutics%2C+Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Byron Robinson, Ph.D., J.D., as Chief Strategy Officer. Dr. Robinson brings 30 years of industry expertise and experience from key strategy roles at large pharma companies, including Merck KGaA, Bayer, and Amgen.